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g.2014.0Abstract Objective: Glutaric acidemia type 1 (GA1) was thought to be a rare disorder in Arab
countries. Recently, a relatively large number of patients with GA1 have been detected in Egypt.
The aim of this work was to: (1) ﬁnd out the commonest clinical characteristics of the disease among
Egyptians presenting with GA1; (2) delineate the demographic factors that may lead to a high prev-
alence of GA1 among Egyptians; (3) Recommend the most suitable strategy to screen for the dis-
ease.
Patients and methods: The study included all patients with GA1 who presented at The Genetics
Unit, Ain Shams University Hospital (GUASH) during the last three years. The information about
patients with GA1 including the epidemiological and clinical data was obtained retrospectively from
patients’ ﬁles.
Results: The authors surveyed data of 26 patients in 23 families who were personally examined
and the diagnosis was conﬁrmed by laboratory data. The mean age of onset of symptoms was
5.8 ± 2.2 months: the mean delay in establishing the diagnosis was 11.73 ± 13.97 months. At the
onset of symptoms, macrocephaly (85%) was the commonest feature of GAI followed by dystonia
(69%), and persistent convulsions (50%). Onset of symptoms occurred during an acute febrile ill-
ness in 68% of patients, which was associated with the worst forms of dystonia (X2 = 12.5,
p=0.14). The frequency of affected Christian families among all affected families was 43%, whichhams University Hospitals, 3
11771, Egypt. Tel.: +20
etics.net, okzaki@gmail.com
Shams University.
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188 O.K. Zaki et al.is signiﬁcantly higher than that expected of the Christian minority in Egypt (6–15%). There has
been no signiﬁcant increase in consanguinity among those Christian families (F= 0.014204) point-
ing to a high gene frequency of GA1 in isolated areas in Upper Egypt.
Recommendation: In the absence of mass newborn screening program, continuous Health Edu-
cation program should be implemented to promote detection of early signs of GA1 such as macro-
cephaly before the occurrence of acute crisis of encephalopathy especially in families with history of
similar patients. We recommend that a nationwide program of extended tandem mass screening
should cover all newborns in Egypt to promote early detection of patients with GA1 and to avoid
the severe consequences of the delay in diagnosis.
 2014 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Glutaric acidemia type 1 (GA1) is an inherited metabolic dis-
order caused by deﬁciency of glutaryl-CoA dehydrogenase,
which is involved in the degradative metabolism of L-lysine,
L-hydroxylysine and L-tryptophan [1]. The defect gives rise to
elevated glutaric acid, 3-hydroxyglutaric acid, glutaconic acid,
and glutarylcarnitine which can be detected by gas chromatog-
raphy/mass spectrometry (organic acids) or tandem mass spec-
trometry (acylcarnitines) [2]. Based on the urinary excretion of
metabolites, GA1 patients are classiﬁed into high and low exc-
retor groups. The low excretor patients are more difﬁcult to
diagnose despite having the same clinical picture and prognosis
of high excretor patients.
Untreated patients have dystonia during infancy resulting
in a high morbidity and mortality. This is associated with stri-
atal injury, which results from encephalopathic crises precipi-
tated by infectious diseases, immunizations and surgery
during a ﬁnite period of brain development [3]. In 10% of pa-
tients the disease may also occur insidiously without clinically
aarent crises [4].
GA1 is generally a rare disorder with an estimated preva-
lence around 1 in 100,000 newborns [5]. However, some com-
munities have a high prevalence such as the Amish Community
[6], Canadian Oji-Cree natives [7] and the Irish travelers [8].
Few patients with GA1 have been reported in Arab coun-
tries; These include six Arab families in Israel and West bank
[9] and sporadic patients in Kuwait, Oman and Arab Emirates
[10,11].
In Egypt, Selim et al. reported one patient with GA1 during
screening of 800 clinically suspected patients with neurometa-
bolic disorders [12]. Three other patients have been reported in
screening of 170 patients referred for GC–MS of urine due to a
suspected metabolic disorder [13]. A larger number of patients
with GA1 have been diagnosed by Genetics Unit Ain Shams
University Hospital (GUASH) in the last three years.
The aim of this work was to: (1) ﬁnd out the commonest
clinical characteristics of the disease among Egyptians present-
ing with GA1; (2) delineate the demographic factors that may
lead to a high prevalence of GA1 among Egyptians; (3) Rec-
ommend the most suitable strategy to screen for the disease.
2. Patients and methods
The study included all patients with glutaric acidemia type 1
who presented at GUASH during the last three years (2010–
2012). GUASH is the center recognized by the Ministry of
Health in Egypt for management of patients with metabolic dis-
orders. Patients included in this study comprise a representativesample of patients with GA1 in Egypt as they are referred from
all over Egypt to GUASH at Ain Shams University in Cairo.
The work was carried out in accordance with the Code of Eth-
ics of the World Medical Association (Declaration of Helsinki)
for experiments involving human after approval of the ethics
committee of Ain Shams University and approval of the par-
ents of the patients.
All patients have been personally examined at the GUASH
metabolic clinic. The diagnosis was conﬁrmed by elevated level
of C5-DC carnitine in blood using LC MS/MS and/or elevated
3-hydroxyglutaric acid in urine.
The epidemiological and clinical data were obtained retro-
spectively from patient’s ﬁles. This included family history, ori-
gin, religion and consanguinity of parents. The clinical history
was reviewed with emphasis on the age of onset, the presenting
symptoms and signs, duration of illness before referral to our
hospital.
A statistical study of the relation between the commonest
clinical ﬁndings and the laboratory proﬁle of patients at pre-
sentation was done using SPSS program using Pearson Chi
square test and Kruskal–Wallis for association study and Wil-
coxon Rank Sum to study the correlation between the clinical
ﬁndings and the level of C5-DC in blood [14].
3. Results
Twenty six patients from 23 families were included in this
study. There were 9 families (39.1%) in which multiple siblings
were affected, of which 3 were included in this study. The
remaining 6 siblings were deceased and not included in this
analysis.
The mean age of patients was 41.85 months ± 15.5. Sixteen
of the 26 patients were males. The mean age of onset of the dis-
ease was 5.8 ± 2.2 months. The delay between onset of symp-
toms and establishing the diagnosis varied from one month to
12 years (Fig. 1). The mean time needed to establish the diag-
nosis of GA1 was 11.73 months ± 13.97.
Twenty two patients (84.6%) had macrocephaly including a
single patient who received treatment following newborn
screening of siblings of patients (Table 1). He has no other
symptoms or signs of the disease till the age of 9 months (at
the time of preparing this study). The next commonest clinical
feature was severe dystonia (69%). Rapid deterioration within
few days of onset of the disease (acute onset of the disease) oc-
curred in 68% of patients; the associated intercurrent infection
and persistent convulsions occurred in half of patients.
The level of C5-DC varied in patients from 0.36 to
6.4 lmol/L with a mean of 1.97 ± 0.84 lmol/L (normal
value 6 0.34 lmol/L). GC-MS of urine showed a high level
Table 1 Summary of main clinical features in patients with GA1.
Case No. Age of onseta
(months)
Acute
onset
Associated
intercurrent
infection
Macrocephaly
(>95th centile)
Persistent
convulsions
Severe
dystonia
3-OH glutaric
in urine
C5-DC lMol/L
1. 4   +   +++ 1.91
2. 9 + + + + + +++ 1.42
3. 14 + + + + + +++ NAb
4. 7   +   +++ 1.45
5. 1   +   +++ 1.57
6. 6 + + + +  + 0.5
7. 7 +  +  + +++ 1.34
8. 7   +  + +++ NA
9. 2 +  + +  +++ NA
10. 4 + + + + + +++ 0.62
11. 2   + + + +++ 0.76
12. 6 + + + + + +++ 0.36
13. 2 + + + +  +++ 1.38
14. 2 + + +  + +++ 0.37
15. 14 + +   + +++ NA
16. 10 + + +  + +++ 6.4
17. 3 + + + + + +++ 4.48
18. 1     + +++ 5.5
19. 7 +    + +++ 0.9
20. 4   +  + +++ 2.49
21. 0c N/A N/A +   +++ 2.7
22. 7 + + + + + +++ 3.05
23. 6 +     +++ NA
24. 6 + + + + + +++ 0.43
25. 14 + + + + + +++ 3.42
26. 7   + + + +++ 0.4
5.8 ± 2.2d 17(68%) 13 (52%) 22(84.6%) 13(50%) 18(69%) 26(100%) 1.97 ± 0.84d
a The age at which the clinical features of the disease were ﬁrst reported by parents.
b N/A = Not Available.
c Patient was diagnosed during screening of sibs of affected cases.
d Mean and range with 95% statistical conﬁdence.
Figure 1 Distribution of the age of onset and age at diagnosis of patients showing a marked delay in the diagnosis of cases with GAI in
Egypt.
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Figure 2 Distribution of cases in delta and Upper Egypt.
190 O.K. Zaki et al.of 3-hydroxy glutaric acid in urine in all 26 patients. However,
it was mildly elevated in one patient that was reported as a low
excretor GA1 (Table 1).
Pearson Chi-Square test for the association of the mode of
onset with different clinical features, showed no signiﬁcant
association with macrocephaly or convulsions. On the other
hand, there was a signiﬁcant association between associated
intercurrent infection and the occurrence of severe dystonia
(X2 = 12.5 p= 0.14).
The Kruskall Wallis test showed non-signiﬁcant difference
between all categories of onset as regards the level of C5-DC
carnitine in blood. Wilcoxon Rank Sum test also showed no
signiﬁcant correlation between the level of C5-DC carnitine
and the occurrence of macrocephaly, acute febrile onset, severe
dystonia or convulsions.
Ten families out of total 23 families were Christians; most
of those families came from Upper Egypt (7/10) around the
area of Asyut Governorate. In contrast, 12 of the remaining
13 Muslim families were from the Delta region of the Nile
(Fig. 2).
Fourteen families showed variable degrees of consanguinity
with a total coefﬁcient of inbreeding 0.027174 ± 0.01220998 in
the whole sample. This is signiﬁcantly higher than the coefﬁ-
cient of inbreeding among Egyptians which is as high as
0.01010 [15]. The high coefﬁcient of inbreeding was mainly
due to consanguinity in Muslim families (0.3125); On the con-
trary, the coefﬁcient of inbreeding (0.014204) among Christian
families was not signiﬁcantly different from that of the coefﬁ-
cient of inbreeding among Egyptians.
4. Discussion
Following the establishment of a centralized facility for the
management of metabolic disorders at GUASH, a relatively
large number of patients with GA1 have been referred from
all over Egypt. This raised questions about the possibility of
a high prevalence of GA1 among Egyptians, the commonestclinical features in those patients, and the most suitable meth-
od for early diagnosis of the disease.
The study showed that the diagnosis of GA1 has been de-
layed in most patients despite the clear clinical history of the
metabolic disorder, presence of consanguinity and a positive
family history in one third of the families. Patients 4 and 11
were salient examples of unjustiﬁed delay in diagnosis: Patient
4 was only diagnosed, at the age of 40 months, after having an-
other affected sib despite history of consanguinity and similar
affected cousin; the diagnosis of patient 11 was made at the age
of 10 years despite clear history of severe dystonia and a stroke
like attack following acute febrile illness and a similar affected
sib and uncle. This shows the urgent need to train health work-
ers to detect alarming signs of the metabolic disorder especially
in the presence of consanguinity and a family history sugges-
tive of the GA1.
The only signiﬁcant predictive parameter in this study for
the prognosis was the association between the occurrence of
severe dystonia and the acute onset of the disease associated
with intercurrent infection. A similar ﬁnding was reported by
Strauss and coworkers who found that stroke like attack with
abrupt puatminal necrosis is the most distinctive and crippling
manifestation in GA1, and the major determinant of morbidity
and mortality [16]. Several studies also showed that morbidity
and mortality are high in patients who have had acute enceph-
alopathic crisis precipitated by Intercurrent febrile illness,
immunization, or surgical intervention [3,17]. Other clinical
and laboratory parameters, that were studied in this work,
did not have a signiﬁcant effect on the prognosis of the disease
including the level of C5-DC in blood and 3-hydroxyglutaric
acid in urine.
The geographic distribution of patients did not show a sig-
niﬁcant variation between regions of Egypt that referred GA1
patients to our clinic. However, a signiﬁcant variation in the
geographic distribution was detected when the religion of the
families was considered; most of the Christian patients were
from Upper Egypt (six out of 10 families) while the Muslim
families were distributed in Cairo and Delta region (12 out
of 13 families).
The overall frequency of affected Christian families was
43%, which is signiﬁcantly higher than the expected for the
proportion of the Christian minority in Egypt (6–15%)
[18,19] (Fig. 3).
The signiﬁcantly high coefﬁcient of in breeding in the whole
sample shows that consanguinity played a major role in the
occurrence of GA1 in Egypt in the Delta region where 65%
of affected families were consanguineous. Health education
against the traditional ﬁrst cousin marriage and screening of
newborns of consanguineous couples are recommended
On the contrary, the consanguinity rate among Christian
families was not signiﬁcantly different from that in the general
population [20]. In addition, the coefﬁcient of inbreeding was
far less than that among Muslim families with GA1. These
observations point to the possibility of a genetic drift that
led to the widespread of carriers among small Christian iso-
lates in Upper Egypt (villages in Upper Egypt that developed
through inbreeding of Christian families living in the same vil-
lage); however, consanguinity was not a prerequisite for the
occurrence of disease in such isolated areas.
In the absence of a national screening program, selective
screening is recommended in such populations [3]. This should
cover several provinces in Upper Egypt to detect patients with
Figure 3 The distribution of Muslim (red) and Christian (yellow) families with ga1 in Egypt generated by Epi-info program [23].
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rious neurologic complications in the endemic area.
Measuring the level of 3-hydroxyglutaric acid in urine using
GC/MS was diagnostic in all cases. However, GC/MS study of
urine is difﬁcult to apply as a screening procedure. This is due
to the difﬁculty of sampling and the lengthy procedure that re-
quires special laboratories that are not available in Egypt.
Out of 26 patients with GA1, only one patient had a low
excretory GA1 proﬁle in urine; but, the level of C5DC was still
high in blood in that case. Thus, Tandem mass screening for
C5DC should be the most suitable method to screen newborns
for GAI in Egypt; the possibility of false negative cases will be
low compared to populations with a high incidence of low
excretory phenotype. The latter require DNA screening for
prevalent mutations to avoid false negative results [21]. A ma-
jor advantage of tandem mass screening is that several other
metabolic disorders are detectable using the same sample with
high throughput machines that are readily available in several
laboratories in Egypt. The same blood sample that is collected
in the national screening program for hypothyroidism may be
used without any added cost for sampling [22].
Until such a screening program is applied in Egypt, all
efforts should be directed to raising the level of awareness ofphysicians to the alarming features that are commonly associ-
ated with GA1 such as macrocephaly, acute onset of neurolog-
ical signs with our without intercurrent infection and dystonia.
Physicians should give more time to recording of family history
of consanguinity and occurrence of similar cases; it is unaccept-
able to diagnose two or three sibs as having encephalitis with-
out ordering a metabolic workup. Primary care physicians
should immediately refer suspected patients to tertiary care cen-
ter that has access to diagnostic procedures such asMS/MS and
GC/MS.
Recommendation: The study shows that extended tandem
mass screening for IEMs should cover all newborns in Egypt
to prevent the severe consequences of the delay in diagnosis;
this is especially important in Upper Egypt and isolated rural
areas where founder effect and consanguinity may lead to high
prevalence of IEMs. In addition molecular study is required to
characterize the prevalent mutations. This will pave the way to
premarital and prenatal screening of couples in endemic areas.
Until screening programs are available, every effort should be
directed to educating physicians in demoted areas to pick up
early signs of the disease such as macrocephaly. This will pre-
vent deterioration of patients and pave the way for early detec-
tion in sibs of affected cases.
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